A Review on Her-2 Targeted Therapy in Breast Cancer

Abstract

Breast cancer is a form of disease which involves malignant growth of cells in the breast. It is the most common cause of cancer in woman and the highest prevalence of breast cancer is accountable for nearly 26 percent of all women's cancers. Breast cancer has in recent decades been significantly promoted by adding more specific therapies to different sub-types of advanced clinical activity since the discovery of novel treatment aspects related to HER-2 antibody mediated therapy and small molecule inhibitors of HER-2 in breast cancer. The use of HER2 therapies to treat HER2-positive breast cancer patients has led to dramatic survival results in both early and advanced stages of breast cancer. Another approach has focused on effectively inhibiting the HER2 signaling pathway and creating enhanced anti-HER2 therapies such as antibody – drug conjugates. The comprehensive goal of this study was to study the design and synthesis of several small molecule inhibitors of HER-2.